Shelly Lee, MD
Basic profileShelly Lee is an Ophthalmology physician affiliated with Spokane Eye Clinic Ps. OpenAlex indexes 6 publications with 319 citations (h-index 4).
Overview
Scholarship
indexed output and impact (OpenAlex)Publications indexed by OpenAlex. Counts exclude supporting files.
Citations across these publications.
H-index from these publications.
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
Telephone
Practice address and telephone from the federal NPPES registry.
Sign in to view contact details →Industry payments
13 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- ABBVIE INC.Program year20254 payments$177
- ANI Pharmaceuticals, Inc.Program year20254 payments$93
- Astellas Pharma US IncProgram year20251 payment$92
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Nervous system
87.9%Ester Local Anesthetic87.9%Chloroprocaine hcl ophthalmic100%Part B, office-administered≥93 patientsSensory organs
10.5%Antineovascularisation agents9.8%Faricimab-svoa100%Part B, office-administered≥44 patientsVascular Endothelial Growth Factor Inhibitor0.4%Ranibizumab100%Part B, office-administered≥25 patients+ 6 more classes in this area
Cancer & immunology
1.5%Vascular Endothelial Growth Factor Inhibitor1%Aflibercept100%Part B, office-administered≥125 patientsComplement Inhibitor0.5%Pegcetacoplan100%Part B, office-administered≥12 patients+ 1 more class in this area
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- Adalimumab therapy for refractory uveitis: results of a multicentre, open-label, prospective trial
British Journal of Ophthalmology
2013 - The Treatment of Recurrent Central Serous Chorioretinopathy with Intravitreal Bevacizumab
Journal of Ocular Pharmacology and Therapeutics
2011
Similar KOLs
Other experts from the same institution or the same specialty.
No other directory profiles share this institution yet.
Robert Weinreb, MD
University of California San Diego
Emily Chew, MD
National Eye Institute
Carol Shields, MD
Wills Eye Hospital
Harry Quigley, MD
Johns Hopkins University School of Medicine
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments, shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet. Reviewed account links and congress post links can appear separately. Absence of a section means “not yet looked,” never “none found.”